Analysed SELLAS LIFE SCIENCES GROUP I (SLS:NASDAQ) News Sources
SELLAS Life Sciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update
11-08-2026
yahoo.com
Sellas’ Experimental Drug SLS009 Appears To Be Leading The CDK9 Race, Says Alliance Global – Analyst Sees About 200% Upside Potential
12-08-2026
stocktwits.com
Sellas CEO Angelos Stergiou Highlights Pediatric Leukemia Study That ‘Directly Supports’ Scientific Basis Of Regal Trial
17-08-2026
stocktwits.com
SLS, IBRX Stocks In Focus: Analyst Says Moderna-Merck Cancer Vaccine Success ‘Bodes Well’ For Oncology
21-08-2026
stocktwits.com
SELLAS Life Sciences Group (SLS) Stock Looks Stretched Despite Key AML Trial Progress
21-08-2026
yahoo.com
Is SELLAS (SLS) Turning Sector Hype Into a Durable Cancer Vaccine Story Despite Ongoing Losses?
21-08-2026
yahoo.com
SLS Stock Clocks Three Straight Weeks Of Gains On Cancer Vaccine Spillover, REGAL Trial Data Anticipation
21-08-2026
stocktwits.com
SLS Stock Charges Ahead As AML Trial Buzz Builds: Report Claims Regal Hit 80th Event — Retail Isn’t Convinced
24-08-2026
stocktwits.com
What is the current price of SELLAS LIFE SCIENCES GROUP I (SLS:NASDAQ)?
The current price of SELLAS LIFE SCIENCES GROUP I (SLS:NASDAQ) is $14.09.
SELLAS LIFE SCIENCES GROUP I (SLS:NASDAQ) absolute price change since previous trading day?
The absolute price change of SELLAS LIFE SCIENCES GROUP I (SLS:NASDAQ) since the previous trading day is $-0.235.
SELLAS LIFE SCIENCES GROUP I (SLS:NASDAQ) percentage price change since previous trading day?
The percentage price change of SELLAS LIFE SCIENCES GROUP I (SLS:NASDAQ) since the previous trading day is -1.6405%.
What is the most recent average sentiment score for SELLAS LIFE SCIENCES GROUP I (SLS:NASDAQ)?
The most recent average sentiment score for SELLAS LIFE SCIENCES GROUP I (SLS:NASDAQ) is 61 out of 100.
What is the most recent average sentiment for SELLAS LIFE SCIENCES GROUP I (SLS:NASDAQ)?
The most recent sentiment for SELLAS LIFE SCIENCES GROUP I (SLS:NASDAQ) is .
SEC-8K** Filing Available For SELLAS LIFE SCIENCES GROUP I (SLS:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.